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Abstract
Background: Serotonin (5-HT, 5-hydroxytryptamine) activates the Extracellular Signal-Regulated
Kinase (ERK)/ Mitogen-Activated Protein Kinase (MAPK) pathways, in vascular smooth muscle
cells. Parallel MAPK pathways, the c-Jun N-terminal Kinase (JNK) and p38 pathway, are activated
by stimulators of the ERK/MAPK pathway. We hypothesized that 5-HT would activate the JNK and
p38 pathways in rat vascular smooth muscle cells.
Results: Results were determined using standard Western analysis and phosphospecific JNK and
p38 antibodies. No significant activation by 5-HT (10-9 – 10-5 M; 30 min) of the JNK or p38
pathways, as measured by protein phosphorylation, was observed in any of these experiments.
These experiments were repeated in the presence of the serine/threonine phosphatase inhibitor
okadaic acid (1 uM) and the tyrosine phosphatase inhibitor sodium orthovanadate (1 uM) to
maximize any observable signal. Even under these optimized conditions, no activation of the JNK
or p38 pathways by 5-HT was observed. Time course experiments (5-HT 10-5 M; 5 min, 15 min,
30 min and 60 min) showed no significant activation of JNK after incubation with 5-HT at any time
point. However, we detected strong activation of JNK p54 and p46 (5- and 7 fold increases in bands
p54 and p46, respectively over control levels) by anisomycin (500 ng/ml, 30 min). Similarly, a JNK
activity assay failed to reveal activation of JNK by 5-HT, in contrast to the strong stimulation by
anisomycin.
Conclusion: Collectively, these data support the conclusion that 5-HT does not activate the JNK
or p38 pathways in rat vascular smooth muscle cells.
Background
The mitogen-activated protein kinase (MAPK) family
consists of three commonly recognized subgroups: the
extracellular signal-regulated kinase (ERK), the c-jun-N-
terminal kinase (JNK), also known as the stress activated
protein kinase (SAPK) and the p38 kinase. While many
actions have been associated with activation of the ERK
pathway, two particular functions of interest to our labo-
ratory are mitogen-stimulated growth [1] and smooth
muscle cell contraction [2]. Of the three MAPK path-
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ways, activation of the ERK pathway and the intracellu-
lar signaling pathways associated with ERK activation
are the best delineated. Known activators include reac-
tive oxygen species [3,4], growth factors [5], and agonists
of G-protein coupled receptors [6,7]. The two other
MAPK pathways, the JNK and p38 pathways, have been
implicated in a variety of similar cellular functions.
Known activators of the JNK and p38 pathways in vascu-
lar smooth muscle cells include reactive oxygen species
[8,9], mechanical strain [10,11], hypoxia [12] and a vari-
ety of cytokines and growth factors. The mechanisms of
many cellular functions of the JNK and p38 pathways are
not yet clearly defined. The JNK pathway is involved in
apoptosis [13], arginine vasopressin-induced increases
in smooth muscle α -actin in vascular smooth muscle
cells [14] as well as in phosphorylation of transcription
factors c-jun, ATF-2 and ELK-1 and phosphorylation of
Na-K-2CI cotransporter [15]. The p38 pathway has been
implicated in apoptosis [16], neointimal hyperplasia af-
ter vascular injury [17] as well as angiotensin ll-induced
contraction in vascular smooth muscle [18].
Recently, it has been noted that the JNK and p38 path-
ways can be activated by G-protein coupled receptor ag-
onists, notably angiotensin II, in vascular smooth muscle
cells [19,20]. In cardiac myocytes, both the p38 and JNK
pathways have been activated by endothelin-1 (ET-1) and
the α 1 adrenergic receptor agonist phenylephrine [21].
The ability of the JNK and p38 pathways to be activated
by the same agonists of G-protein coupled receptors
which activate the ERK pathway led to the investigation
of 5-HT as a possible activator of the JNK and p38 path-
ways. 5-HT, acting via the 5-HT2A receptor, is a known
activator of the ERK pathway in vascular smooth muscle
cells [2,22]. In these studies we tested the hypothesis
that 5-HT would activate the JNK and p38 pathways in
rat aortic vascular smooth muscle cells.
Results
The ERK pathway
In agreement with previously published studies from our
lab, 5-HT caused a concentration-dependent activation
of the ERK pathway (figure 1). This activation occurs
maximally at five minutes of stimulation and returns to
basal levels by thirty minutes [23]. This time course of
activation is consistent with that of other G-protein cou-
pled receptors.
The p38 pathway
The p38 pathway has demonstrated a different time
course of activation via G-protein coupled receptors
than the ERK pathway [24]. Using the time point (30
min) at which angiotensin II demonstrates maximal
stimulation of the JNK pathway we performed a concen-
tration response curve (10-9 – 10-5 M) to 5-HT in vascu-
lar smooth muscle cells. Western analysis using
phosphospecific antibodies was used to measure activa-
tion the p38 pathway. A total or non-phosphospecific an-
tibody was used to ensure equal loading of p38 protein.
After thirty-minutes of incubation with 5-HT (10-9 – 10-
5 M), there was no enhanced phosphorylation of p38 (fig-
ure 2, bottom). In contrast, incubation with anisomycin
(500 ng/ml) induced significant phosphorylation of p38
(2-fold above basal). These data suggest that 5-HT does
not activate the p38 pathway in rat vascular smooth
muscle cells despite the ability of other agonists to acti-
vate the pathway in these cells.
The JNK pathway
Figure 3 shows that thirty minutes of incubation with 5-
HT (10-9 – 10-5 M) resulted in a trend towards a modest
increase in phosphorylation of the p46 JNK isoform.
This trend, however, was not statistically significant. In
contrast, anisomycin (500 ng/ml) induced significant
phosphorylation of the p46 JNK isoform (5–7 fold above
basal). Both the p54 and p46 bands were analyzed by
densitometry (data for p54 not shown). However, incu-
bation with 5-HT did not produce statistically significant
activation in either band when compared to vehicle.
These data suggest that 5-HT does not substantially acti-
vate the JNK pathway in vascular smooth muscle cells.
However, the data obtained with anisomycin provides
evidence that this pathway can be activated in these cells.
To confirm that thirty minutes was an optimal time point
for observing 5-HT-induced phosphorylation of JNK, we
Figure 1
Top: Blot of 5-HT-induced stimulation of the ERK/MAPK
pathway in rat aortic vascular smooth muscle cells as meas-
ured by use of a phosphospecific ERK/MAPK antibody. Den-
sitometry measurements are for the 42 kDa band. Blot is
representative of four experiments. Bottom: Total ERK/
MAPK antibody recognizes nonphosphorylated forms as well
as phosphorylated protein. Densitometry measurements are
for the 42 kDa band.BMC Pharmacology 2001, 1:8 http://www.biomedcentral.com/1471-2210/1/8
next performed a time course of JNK phosphorylation
after exposure to 5-HT in rat vascular smooth muscle
cells. At no time point (5 min, 15 min, 30 min and 60
min) did 5-HT (10-5 M) enhance JNK phosphorylation
above basal levels (figure 4). These data fail to support a
role for 5-HT-induced activation of the JNK pathway in
vascular smooth muscle cells.
To demonstrate that a G-protein coupled receptor ago-
nist could activate the JNK pathway in our vascular
smooth muscle cells, we incubated the cells with angi-
otensin II (10-9 – 10-5 M) for thirty minutes. Angiotensin
II (10-8 – 10-5 M) produced a significant increase in the
level of JNK phosphorylation (figure 5). The authors
speculate that the differences in the level of phosphoryla-
tion of the p46 JNK isoform in the vehicle treatment
group maybe due to differences in the JNK expression
over time in cultured cells. The cells used in these exper-
iments were of a later passage than those used for the 5-
HT incubation studies. These data, in addition to that ob-
tained with anisomycin, demonstrate that in these vas-
cular smooth muscle cells the JNK pathway can be
activated.
Due to the trend toward increased phosphorylation of
both the p46 and p54 JNK isoforms by 5-HT, we next
performed JNK activity assays to determine whether 5-
Figure 2
Top: Blot of 5-HT-induced stimulation of the p38 pathway in
rat aortic vascular smooth muscle cells as measured by use of
a phosphospecific p38 antibody. Blot is representative of four
experiments. Total anti-p38 antibody recognizes nonphos-
phorylated forms as well as phosphorylated protein. Bottom:
Densitometry measurements for p38 kDa. Bar graphs repre-
sent means and vertical bars the SEM for N = 4. * = statistical
difference for response in vehicle-incubated cell cultures.
Figure 3
Top: Blot of 5-HT-induced (10-9 – 10-5 M) stimulation (30
minutes) of the JNK pathway in rat aortic vascular smooth
muscle cells as measured by use of a phosphospecific JNK
antibody. Blot is representative of four experiments. Middle:
Total anti-JNK antibody recognizes nonphosphorylated
forms as well as phosphorylated protein. Bottom: Densitom-
etry measurements are for the 46 kDa band. Bar graphs rep-
resent means and vertical bars the SEM for N = 4. * =
statistical difference for response in vehicle-incubated cell
cultures.BMC Pharmacology 2001, 1:8 http://www.biomedcentral.com/1471-2210/1/8
HT had any significant effect on kinase activity. This as-
say was chosen to ensure that the western analyses used
were sufficiently sensitive to detect changes in the activa-
tion of the JNK pathway. There was no significant differ-
ence in the levels of activity at any concentration of 5-HT
(10-9 – 10-5 M) after thirty minutes of incubation in vas-
cular smooth muscle cells (figure 6). In contrast, ani-
somycin (500 ng/ml, 30 min) produced a significant
increase in JNK activation (approximately 2-fold above
basal). These data, in combination with the above find-
ings, do not support a role for 5-HT in the activation of
the JNK pathway in vascular smooth muscle cells.
Conclusions
5-HT is an activator of the ERK pathway in vascular
smooth muscle cells. In contrast, 5-HT appears to be un-
able to activate the JNK and p38 pathways in vascular
smooth muscle cells. No observable changes in activa-
tion, as measured by phosphorylation status, were seen
at any of the 5-HT concentrations (10-9 – 10-5 M) or time
points (5 min, 30 min, 60 min and 2 hr) examined. The
data from the kinase activity assay also demonstrated no
activation of the JNK pathway by 5-HT.
The mitogen-activated protein kinase family is associat-
ed with many cellular functions. The ability of 5-HT to
activate the ERK pathway is consistent with 5-HT's role
as a mitogenic stimulus and vasoconstrictor. Several va-
soactive G-protein coupled agonists, including angi-
otensin II and endothelin, have also been shown to
activate the ERK pathway in vascular smooth muscle
cells [6,21]. These same hormones also activate the JNK
and p38 pathways. These agonists have different time
course and concentration profiles for activation of the
different MAPK pathways. ERK activation by angi-
otensin II and 5-HT occurs at relatively lower agonist
concentrations and within five minutes of stimulation
(19,23). The activation of p38 and JNK pathways by an-
giotensin II and endothelin occurs at higher concentra-
tions of agonist and requires a longer incubation with the
stimulus [18,19,25]. There are data which also suggest
that different signal transduction pathways are utilized
for the different pathways [25–27]. This differential acti-
vation of MAPK pathways is most likely due to the role
that each plays in the cell. The ERK pathway is associated
with growth where as the p38 and JNK pathways are
"stress response" pathways.
In light of data for the other G-protein coupled receptor
agonists, the inability of 5-HT, also G-protein coupled re-
ceptor, was initially surprising. While 5-HT has never
been shown to increase activation of either the p38 or
JNK pathways, it has been linked to ERK activation. The
5-HT2A receptor is the primary serotonergic receptor
which couples to activation the ERK pathway in vascular
smooth muscle cells [28]. 5-HT's inability to activate the
JNK and p38 pathways may be due to a lack of coupling
of the 5-HT2A receptor signaling pathway to the compo-
nents in the JNK and p38 pathways.
It has recently been suggested that G-protein coupled re-
ceptors with PDZ domains, SH2-containing domains
and PTB domains participate in protein-protein interac-
tions with partners other than G-proteins, such as Grb2
and JAK2, which may allow these receptors to bypass the
G-proteins and utilize other signaling cascades (29). This
ability of G-protein coupled receptors to modulate the
signal cascade used, independent of G-proteins, suggests
Figure 4
Top: Blot of 5-HT-induced (10-5 M) stimulation (5 min, 15
min, 30 min and 60 min) of the JNK pathway in rat aortic vas-
cular smooth muscle cells as measured by use of a phosphos-
pecific JNK antibody. Blot is representative of four
experiments. Middle: Total anti-JNK antibody recognizes
nonphosphorylated forms as well as phosphorylated protein.
Bottom: Densitometry measurements are for the 46 kDa
band. Bar graphs represent means and vertical bars the SEM
for N = 4. * = statistical difference for response in vehicle-
incubated cell cultures.BMC Pharmacology 2001, 1:8 http://www.biomedcentral.com/1471-2210/1/8
a broader range of interaction with signaling compo-
nents. This may provide one explanation for the 5-HT ac-
tivation of the ERK and its lack of effect on the JNK and
p38 pathways.
Another possible explanation for the differential activa-
tion of the MAPK pathways by 5-HT may relate to the
varied roles 5-HT in different cell types and the multiple
receptors which mediate these roles. When examining
the physiological role of 5-HT in other cell types, in re-
gards to apoptosis and cellular responses to stress, 5-HT
is generally anti-apoptotic [30–32]. In particular, in
neuronal cells the 5-HT1A receptor is upregulated under
conditions of cellular stress and is anti-apoptotic
[33,34]. The anti-apoptotic effects of 5-HT maybe due to
scavenging of reactive oxygen species [35] as well as
stimulation of the ERK pathway which results in inhibi-
tion of a caspase-3-like enzyme [32]. There are no cur-
rently published studies examining the role of 5-HT as an
anti-apoptotic factor in vascular smooth muscle cells. It
may be that under stressful conditions, such as a disease
state or a loss of nutrients which occurs in a state of
ischemia, the smooth muscle cells upregulate a new com-
plement of 5-HT receptors [33–35]. These new receptors
maybe involved in activation of the ERK, p38 and JNK
pathways, but the studies presented here do not directly
address this issue. They do, however, support the conclu-
sion that the 5-HT2A receptor does not activate the p38
orJNK pathways in rat vascular smooth muscle cells.
Methods
Aortic smooth muscle cell culture
Vascular smooth muscle cells were derived from the aor-
ta of male Sprague-Dawley rats by an explant method
previously described [36]. The smooth muscle cells were
plated on to P-100's and grown to confluence. The cells
were used between passages 2 and 9. The cells were pos-
itively stained for smooth muscle α -actin (Oncogene Re-
search Products, Boston, MA; Fluorescein labeled goat
anti-mouse secondary antibody, Molecular Probes, Eu-
gene, OR) with each new isolation.
Aortic smooth muscle cells experiments
Cells (P-100 plates) were switched to physiological salt
solution (4 ml) [consisting of (in mmol/L) NaCI, 103;
KCI, 4.7; KH2PO4, 1.18; MgSO4 • 7H2O, 1.17; CaCl2 •
2H2O, 1.6; NaHCO3, 14.9; dextrose, 5.5; and
CaNa2EDTA, 0.03] for one hour prior to addition of ag-
onist. At this time, okadaic acid (1 µM), sodium or-
thovanadate (1 µM) and PD098059 (10 µM) or vehicle
(0.1-.5 %DMSO) was added and allowed to equilibrate
for one hour. PD098059, an inhibitor of MEK activation,
was included in all experiments, except the ERK activa-
tion experiments, to increase the specificity of the phos-
pho-JNK antibody which recognizes the 44 and 42 kDa
ERK bands as well as bands at 54 and 46 kDa. In the
presence of PD098059, the bands at 42 and 44 kDa were
significantly reduced. Each dish was incubated with one
agonist concentration [5-HT (10-9 – 10-5 M), angiotensin
II (10-9 – 10-5 M) or anisomycin (500 ng/ml [37])] for
thirty minutes. Plates were placed on ice and incubation
buffer aspirated. Plates were washed with ice-cold phos-
phate-buffered saline containing sodium orthovanadate
as a tyrosine phosphatase inhibitor (10 mM sodium
phosphate, 150 mM NaCI, 1 mM Na3VO4, pH 7.0). Five
hundred microliters of supplemented RIPA lysis buffer
(50 mM Tris-HCI pH 7.5, 150 mM NaCI, 2 mM EGTA,
0.1% Triton X-100, 1 mM PMSF, 10 ug/ml aprotinin, 10
ug/ml leupeptin, 1 mM sodium orthovanadate) were
added to each dish and cells were harvested with a rub-
Figure 5
Top: Blot of angiotensin ll-induced (10-9 – 10-5 M) stimula-
tion (30 minutes) of the JNK pathway in rat aortic vascular
smooth muscle cells as measured by use of a phosphospecific
JNK antibody. Blot is representative of four experiments.
Middle: Total anti-JNK antibody recognizes nonphosphor-
ylated forms as well as phosphorylated protein. Bottom:
Densitometry measurements are for the 46 kDa band. Bar
graphs represent means and vertical bars the SEM for N = 4.
* = statistical difference for response in vehicle-incubated cell
cultures.BMC Pharmacology 2001, 1:8 http://www.biomedcentral.com/1471-2210/1/8
ber policeman. Lysates were centrifuged at 14,000 g for
10 minutes at 4°C. Protein concentrations of the result-
ing supernatant were measured using the BSA method
(Bio-Rad, Hercules, CA). The gels were also stained with
Gel Code Blue® (Pierce, Rockford, IL) to validate equal
loading of protein.
Immunoblotting protocol
Supernatant (4:1 in denaturing loading buffer, boiled 5
minutes) was loaded, separated on 10% denaturing SDS-
polyacrylamide gels, and transferred to Immobilon-P
membranes. Membranes were blocked for 3–4 hours in
Tris buffer saline + Tween-20 (0.1%; TBS-T) containing
4% chick egg ovalbulmin and 0.025% sodium azide. Rab-
bit anti-phospho Erk MAPK (1:5000, Promega, Madi-
son, Wl), rabbit anti-phospho JNK MAPK (1:5000,
Promega, Madison Wl), rabbit anti-phospho p38 MAPK
(1:1000, Cell Signaling, Beverly, MA), mouse anti-total
Erk (1:5000, Zymed, San Francisco, CA) rabbit anti-total
JNK MAPK (1:5000, Santa Cruz BioTechnologies, Santa
Cruz, CA) or rabbit anti-total p38 MAPK (1:1000, Cell
Signaling, Beverly, MA) were incubated with blots over-
night (4°C). Following washes, secondary antibody
linked to horseradish peroxidase [anti-rabbit (1:2000,
Zymed Laboratories, S. San Francisco, CA) or anti-
mouse (1:7500, Amersham, Arlington Heights IL)] was
added for one hour and incubated with blots at 4°C. En-
hanced chemiluminescence was performed using stand-
ard reagents (Amersham Laboratories, Arlington
Heights, IL).
Kinase activity assay protocol
Primary vascular smooth muscle cell preparations were
treated with agonists as described above. They were then
lysed in a protein kinase lysis buffer [50 mM HEPES, pH
7.5, 150 mM NaCI, 1.5 mM MgCI2, 1 mM EGTA, 1 mM
sodium vanadate, 50 mM sodium fluoride, 20 mM beta-
glycerophosphate, 10% (vol/vol) glycerol, 1% (vol/vol)
Triton X-100, and protease inhibitors (1 mM PMSF, 1
ug/ml pepstatin A1, 1 ug/ml leupeptin, and 1 ug/ml apro-
tinin]. Equal protein amounts of each cell lysate (usually
100 ug) were incubated for 3 h at 4°C in the presence of
purified GST-c-Jun-(1–79) bound to glutathione-agar-
ose beads (2.8 ug GST-c-Jun/ul beads) as previously de-
scribed [38]. Beads were washed 2 times with HNTG
buffer (HEPES 20 mM pH7.5, NaCI 150 mM, Triton X-
100 0.10%, glycerol 10%) followed by an additional
washing with HNTG buffer + 1% bovine serum albumin
(BSA). Samples were then centrifuged at 13,000 rpm for
2 min and the supernatant was discarded. The pellets
were washed 2 times with HNTG buffer and 2 times with
JKAW buffer (HEPES 25 mM, glycerol 10%, MgCl2 20
mM, Na3VO4 0.1 mM, beta-glycerophosphate 12.5 mM,
EGTA 0.5 mM, NaF 0.5 mM). The pellets were then re-
suspended in 50.5 µl JKAW reaction buffer containing
20 µCi [-32P] ATP and 50 µM unlabeled ATP. After 30
min at 37°C, reactions were terminated by the addition of
8 ul SDS loading buffer, samples were boiled and sepa-
rated by SDS-PAGE. Proteins were transferred to stabi-
lized nitrocellulose membranes and the bands
corresponding to phosporylated c-Jun were counted by a
phosphorimager (Storm model 860, Molecular Dynam-
ics, Sunnyvale CA).
Data analysis
Cell experiments were performed three or four times
with each repetition of the experiment being performed
in cells from explants derived from different animals.
Thus, experiments are representative of responses of 3 or
4 different animals. Unpaired Student's t tests were used
where appropriate in comparing two group responses
and a one way ANOVA test was used when comparing re-
sponses of three or more groups (p < 0.05 considered
statistically significant). Phosphorimager data was cap-
tured using Image Quant 5.1 software (Molecular Dy-
namics, SunnyVale, CA). Quantitation of all band
densities was performed using the public domain NIH
Image (v.1.62).
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